535 related articles for article (PubMed ID: 36420910)
21. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
22. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
24. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Brain Amyloid Deposition and Cortical Glucose Metabolism Between Clinic- and Community-Based Cohort.
Yabuuchi K; Kimura N; Masuda T; Matsubara E
J Alzheimers Dis; 2023; 95(1):299-306. PubMed ID: 37483008
[TBL] [Abstract][Full Text] [Related]
26. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
Rodriguez-Vieitez E; Kumar A; Malarte ML; Ioannou K; Rocha FM; Chiotis K
Methods Mol Biol; 2024; 2785():195-218. PubMed ID: 38427196
[TBL] [Abstract][Full Text] [Related]
27. Early after Administration [11C]PiB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery.
Tiepolt S; Luthardt J; Patt M; Hesse S; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2019; 68(1):65-76. PubMed ID: 30636731
[TBL] [Abstract][Full Text] [Related]
28. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
29. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
30. [Application of positron emission tomography in evaluation of Alzheimer's disease rat model].
He TT; Zhang JM; Wang RM; Yao SL; Tian JH
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(13):924-7. PubMed ID: 20646515
[TBL] [Abstract][Full Text] [Related]
31. Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.
Nam MH; Ko HY; Kim D; Lee S; Park YM; Hyeon SJ; Won W; Chung JI; Kim SY; Jo HH; Oh KT; Han YE; Lee GH; Ju YH; Lee H; Kim H; Heo J; Bhalla M; Kim KJ; Kwon J; Stein TD; Kong M; Lee H; Lee SE; Oh SJ; Chun JH; Park MA; Park KD; Ryu H; Yun M; Lee CJ
Brain; 2023 Jul; 146(7):2957-2974. PubMed ID: 37062541
[TBL] [Abstract][Full Text] [Related]
32. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
[TBL] [Abstract][Full Text] [Related]
33. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
[TBL] [Abstract][Full Text] [Related]
34. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
[TBL] [Abstract][Full Text] [Related]
35. Association between Benton Visual Retention Test Scores and PET Imaging in Elderly Adults.
Abe M; Kimura N; Sasaki Y; Eguchi A; Matsubara E
Curr Alzheimer Res; 2021; 18(11):900-907. PubMed ID: 34875990
[TBL] [Abstract][Full Text] [Related]
36. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
37. Early detection of Alzheimer's disease using PiB and FDG PET.
Cohen AD; Klunk WE
Neurobiol Dis; 2014 Dec; 72 Pt A():117-22. PubMed ID: 24825318
[TBL] [Abstract][Full Text] [Related]
38. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 18F-FDG and PiB PET in cognitive impairment.
Lowe VJ; Kemp BJ; Jack CR; Senjem M; Weigand S; Shiung M; Smith G; Knopman D; Boeve B; Mullan B; Petersen RC
J Nucl Med; 2009 Jun; 50(6):878-86. PubMed ID: 19443597
[TBL] [Abstract][Full Text] [Related]
40. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
